Elise MILLER;Merck Sharp & Dohme Corp.;Justin David MOSER;Pavithra SUNDARARAJAN;Angela M. WAGNER;Agam SHETH;Adam SOCIA
发明人:
Agam SHETH,Pavithra SUNDARARAJAN,Elise MILLER,Justin David MOSER,Adam J SOCIA,Angela M WAGNER
申请号:
US15537564
公开号:
US20170368031A1
申请日:
2015.11.06
申请国别(地区):
US
年份:
2017
代理人:
摘要:
The present disclosure is directed to solid dispersion formulations comprising an NS5A inhibitor compound, elbasvir (dimethyl N,N′-([(6S)-6-phenylindolo [1,2- c][1,3]benzoxazine-3,10-diyl]bis {1H-imidazole-5,2-diyl-(2S)-pyrrolidine-2,1-diyl[(2S)-3-methyl-l-oxobutane-1,2-diyl]})di-carbamate), or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable polymer, and optionally a pharmaceutically acceptable surfactant. The present disclosure is also directed to solid dispersion formulations, blended compositions and pharmaceutical dosage forms containing or made from these solid dispersion formulations, and the methods for making these solid dispersion formulations, blended compositions and pharmaceutical dosage forms.